Do GLP-1 drugs cause gallbladder problems?
Last updated September 3, 2026.
GLP-1 drugs raise the risk of gallstones and gallbladder inflammation modestly, and rapid weight loss itself is part of the reason. Both the Wegovy and Zepbound labels include an acute gallbladder disease warning. In Wegovy's adult weight-reduction trials, cholelithiasis was reported by 1.6% of treated patients versus 0.7% on placebo. In Zepbound's pooled trials, cholelithiasis occurred in 1.1% versus 1% on placebo, cholecystitis in 0.7% versus 0.2%, and cholecystectomy in 0.2% versus no placebo patients. The mechanism is twofold: fast weight loss from any method shifts bile toward stone formation, and GLP-1 receptor activation reduces gallbladder contraction, so bile lingers. The labels advise gallbladder studies and follow-up if cholelithiasis is suspected. In practice, most users never have a gallbladder issue. The job is to recognize one if it starts: steady or worsening pain in the upper right abdomen, pain that radiates to the back or right shoulder blade, fever with abdominal pain, or jaundice. Those symptoms deserve same-day medical attention, because an infected or obstructed gallbladder escalates quickly.
What to do
- Know the odds: gallbladder events affected roughly 1 to 2 in 100 trial participants, not most users.
- Lose steadily, not violently: extremely rapid loss concentrates bile and raises stone risk from any method.
- Memorize the pain pattern: upper right or mid-abdomen pain after meals, possibly reaching the back or right shoulder, plus fever or vomiting, means get seen promptly.
- Watch for jaundice: yellow skin or eyes with abdominal pain is urgent.
- Mention history: if you have had gallstones before, tell your prescriber before starting a GLP-1.
Related questions
- What are the side effects of GLP-1 drugs?
- What happens when you stop taking Ozempic?
- Can I get GLP-1 medication without diabetes?
- What blood tests do I need before a weight loss drug?